Short Interest in Biotech Is Mixed (ALXN, AMGN, ARNA, BIIB, CELG, DNDN, GILD, ILMN, ONXX, PCYC, REGN, VRTX, VVUS, IBB)

Photo of Trey Thoelcke
By Trey Thoelcke Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

We have tracked the key short interest changes in the following biotech and emerging pharma companies: Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Amgen Inc. (NASDAQ: AMGN), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Biogen Idec Inc. (NASDAQ: BIIB), Celgene Corp. (NASDAQ: CELG), Dendreon Corp. (NASDAQ: DNDN), Gilead Sciences Inc. (NASDAQ: GILD), Illumina Inc. (NASDAQ: ILMN), Onyx Pharmaceuticals Inc. (NASDAQ: ONXX), Pharmacyclics Inc. (NASDAQ: PCYC), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) and VIVUS Inc. (NASDAQ: VVUS). We also tracked the iShares Nasdaq Biotechnology (NASDAQ: IBB) against the group.

The short interest in biotech stocks is mixed, judging by the short interest changes between the September 28 and October 15 settlement dates. There were notable swings in shares sold short from Biogen Idec, Gilead Sciences and VIVUS. Short interest also was mixed in the previous period.

Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) short interest rose 2.5% between September 28 and Octber 15 to 5.16 million shares. Days to cover ticked back up above five.

Amgen Inc. (NASDAQ: AMGN) saw short interest grow 4.9% to 13.30 million shares. That was the highest number of shares since June.

Arena Pharmaceuticals Inc. (NASDAQ: ARNA) short interest shrank 0.5% to 47.44 million shares. That ended a streak of four consecutive increases. Short interest was 22% of the float.

Biogen Idec Inc. (NASDAQ: BIIB) shares sold short fell 9.6% to 1.68 million, its lowest level this year. Days to cover remains less than two. Short interest is less than 1% of the float.

Short interest in Celgene Corp. (NASDAQ: CELG) climbed 7.3% to 5.27 million shares. Days to cover remains just under two.

Dendreon Corp. (NASDAQ: DNDN) short interest increased 2.3% to 46.88 million shares. This was 31% of the float. Days to cover jumped to more than 15 from less than nine in the previous period.

Gilead Sciences Inc. (NASDAQ: GILD) short interest jumped 11.8% to 29.12 million shares. This followed a more than 26% increase in shares sold short in the previous period.

Illumina Inc. (NASDAQ: ILMN) saw short interest rise 2.2% to 28.37 million shares. That was the seventh consecutive period of increasing short interest. Short interest rose to 23.4% of the float.

Onyx Pharmaceuticals Inc. (NASDAQ: ONXX) shares sold short increased 2.1% to 6.10 million. The average daily volume was at its lowest level since March. Short interest was 9.5% of the float.

Pharmacyclics Inc. (NASDAQ: PCYC) short interest retreated 2.0% to 4.40 million shares. That was the lowest level this year. Days to cover doubled from the previous period to 12.

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) short interest rose about 4% to 5.18 million shares, essentially reversing the decline in the previous period. Short interest ticked up to 6.9% of the float.

Short interest in Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shrank 5.6% to 6.67 million shares. The average daily volume was at its highest since June.

VIVUS Inc. (NASDAQ: VVUS) short interest was 11.3% higher to 16.92 million shares. Days to cover rose to more than five. Short interest was 16.9% of the float.

To show how the sector has held up: the iShares Nasdaq Biotechnology (NASDAQ: IBB) ETF closed at $142.33 on the same date. Its current 52-week range is $92.15 to $148.54.

Trey Thoelcke

Photo of Trey Thoelcke
About the Author Trey Thoelcke →

Trey has been an editor and author at 24/7 Wall St. for more than a decade, where he has published thousands of articles analyzing corporate earnings, dividend stocks, short interest, insider buying, private equity, and market trends. His comprehensive coverage spans the full spectrum of financial markets, from blue-chip stalwarts to emerging growth companies.

Beyond 24/7 Wall St., Trey has created and edited financial content for Benzinga and AOL's BloggingStocks, contributing additional hundreds of articles to the investment community. He previously oversaw the 24/7 Climate Insights site, managing editorial operations and content strategy, and currently oversees and creates content for My Investing News.

Trey's editorial expertise extends across multiple publishing environments. He served as production editor at Dearborn Financial Publishing and development editor at Kaplan, where he helped shape financial education materials. Earlier in his career, he worked as a writer-producer at SVE. His freelance editing portfolio includes work for prestigious clients such as Sage Publications, Rand McNally, the Institute for Supply Management, the American Library Association, Eggplant Literary Productions, and Spiegel.

Outside of financial journalism, Trey writes fiction and has been an active member of the writing community for years, overseeing a long-running critique group and moderating workshop sessions at regional conventions. He lives with his family in an old house in the Midwest.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618